Citius Oncology (CTOR) Change in Account Payables (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Change in Account Payables data on file, last reported at $1.5 million in Q1 2026.

• On a quarterly basis, Change in Account Payables fell 26.88% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $3.9 million, a 70.18% increase from a year earlier, with the FY2025 full-year figure at $9.5 million, down 33.27% from the prior year.
• Change in Account Payables for Q1 2026 stood at $1.5 million, up from -$2.8 million in the prior quarter.
• Over the last five years, Change in Account Payables for CTOR reached as high as $4.6 million in Q3 2025 and fell as low as -$2.8 million in Q4 2025.
• Historically, Change in Account Payables has averaged $563619.2 across 4 years, with a median of $602939.0 in 2025.
• On a YoY basis, Change in Account Payables climbed as much as 360.51% in 2025 and fell as far as 220.81% in 2025.
• Year by year, Change in Account Payables stood at -$1.1 million in 2023, then soared by 312.87% to $2.3 million in 2024, then tumbled by 220.81% to -$2.8 million in 2025, then jumped by 153.64% to $1.5 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were $1.5 million in Q1 2026, -$2.8 million in Q4 2025, and $4.6 million in Q3 2025.